search
Back to results

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Primary Purpose

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
SL-279252
Sponsored by
Shattuck Labs, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Squamous Cell Carcinoma of the Head and Neck

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply.

  1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations.
  2. Subject has a histologically confirmed diagnosis of one of the following unresectable locally advanced or metastatic malignancies: melanoma, non-small cell lung cancer (squamous, adeno, or adeno-squamous), urothelial cancer, squamous cell carcinoma of the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of the anal canal, squamous cell carcinoma of the skin, renal cell cancer, Hodgkin's lymphoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (MMRD) solid tumors excluding CNS malignancies. MSI and MMRD testing results as per institution is acceptable.

    • Head and neck cancers: Subjects must have primary tumor locations in the oropharynx, oral cavity, hypopharynx, or larynx. Primary tumor sites of nasopharynx, maxillary sinus, paranasal, and unknown primary are excluded.
    • Non-small cell lung cancers: Subjects with a known EGFR sensitizing (activating) mutation or an ALK fusion are excluded.
  3. Subject must have received, been intolerant to, or is ineligible for standard therapy (per local guidelines and approvals) or have a malignancy for which there is no approved therapy considered standard of care.
  4. Age 18 years and older.
  5. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  6. Has measurable disease by iRECIST (solid tumors) or RECIL 2017 (lymphoma). Refer to Appendix Sections 16.6 and 16.7 for details on criteria of measurable disease.
  7. Has life expectancy of greater than 12 weeks.
  8. Laboratory values must meet the following criteria. Laboratory parameter Threshold value

    • Absolute lymphocyte count (ALC) ≥ 0.8 x 109/liter (L)
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support
    • Platelet count ≥ 50 x 109/L

    Laboratory parameter Threshold value

    • Hemoglobin (Hgb) > 9.0 g/dL with no blood transfusions for at least 5 days prior to D1 of investigational product (IP; SL-279252)
    • Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/min (modified Cockcroft-Gault)
    • ALT/AST ≤ 3 x ULN
    • Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is <35% and total bilirubin is ≤ 3.0 x ULN
    • Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) ≥ lower limit of normal (LLN) per institutional threshold. If LLN is not defined for a given institution, then ejection fraction must be ≥50 %.
  9. Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP. NOTE: FCBP unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally postmenopausal for at least 12 consecutive months (see Appendix Section 16.2 for additional details). Documentation of postmenopausal status must be provided. FCBP should use an acceptable method of contraception (see Appendix Section 16.2) to avoid pregnancy during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of IP. FCBP must start using acceptable contraception at least 14 days prior to D1 of IP.
  10. Male subjects with female partners must have azoospermia from a prior vasectomy or underlying medical condition or agree to use an acceptable method of contraception during treatment and for 30 days (which exceeds 5 half-lives) after last dose of SL-279252 (see Appendix Section 16.2). Male subjects of reproductive potential must start using acceptable contraception at least 14 days prior to D1 of treatment with SL-279252 as per Appendix Section 16.2.
  11. All AEs resulting from prior anti-cancer immunotherapy have resolved (NOTE: exceptions include alopecia, vitiligo, and endocrinopathies adequately treated with hormone replacement).

    • Subjects that were discontinued from prior PD-1/L1 therapy due to immune-related adverse events are not eligible

  12. Recovery from toxicities from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade toxicities (e.g., alopecia, ≤ Grade 2 lymphopenia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy) may be allowed at the discretion of the investigator if considered clinically insignificant. Please consult the Sponsor Medical Monitor to discuss these cases).

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Has received more than two prior checkpoint inhibitor containing treatment regimens (regimen refers to either monotherapy or combination immunotherapies) or has had prior treatment with an OX40 agonist.

    • Prior PD-1/L1 therapy is not required.

  2. Refractory to last PD-1/L1 inhibitor-based therapy which is defined as disease progression within 3 months of treatment initiation.

    • Subjects must have had clinical benefit (stable disease or response) to last PD-1/L1 inhibitor-based therapy for at least three months to be eligible.

  3. Any anti-cancer therapy within the time intervals noted below prior to first dose (D1) of SL-279252.

    Therapy Washout period Chemotherapy 3 weeks Hormonal therapy 3 weeks PD-1/L1 inhibitor and other immunotherapies not otherwise specified 3 weeks Tumor vaccine 4 weeks Cell-based therapy 8 weeks Other mAbs or biologic therapies 3 weeks Major surgery 2 weeks Radiation (except palliative intent which does not require washout) 2 weeks

  4. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy is prohibited. Concurrent use of hormones for non-cancer related conditions is acceptable.
  5. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of D1 of IP with the following exceptions (i.e., the following are allowed during treatment with or within14 days of D1 of IP):

    • Topical, intranasal, inhaled, ocular, intraarticular corticosteroids
    • Physiological doses of replacement steroid (e.g., for adrenal insufficiency) provided ≤ 10 mg/day of prednisone or equivalent
    • Steroid premedication for hypersensitivity reactions (HSRs; e.g., reaction to IV contrast)
  6. Receipt of live attenuated vaccine within 28 days of D1 of IP.
  7. Active or documented history of autoimmune disease (autoimmune disease does not refer to irAEs; for irAEs see inclusion criteria #11). Exceptions include Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism.
  8. Active pneumonitis (i.e. drug-induced, idiopathic pulmonary fibrosis, radiation-induced, etc.).
  9. Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of IP).
  10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal (GI) disease associated with diarrhea within 6 months of D1 of IP.
  11. Clinically significant or uncontrolled cardiac disease including any of the following:

    • Myocarditis
    • Unstable angina within 6 months from D1 of IP
    • Acute myocardial infarction within 6 months from D1 of IP
    • Uncontrolled hypertension
    • New York Heart Association (NYHA) Class II, III or IV congestive heart failure
    • Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia requiring therapy)
  12. Untreated central nervous system (CNS) or leptomeningeal metastases. Subjects with treated CNS metastases must have completed definitive treatment (radiotherapy and/or surgery) > 2 weeks prior to D1 of IP and no longer require steroids.
  13. Women who are breast feeding.
  14. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent.
  15. Another malignancy that requires active therapy and that in the opinion of the investigator and Sponsor would interfere with monitoring of radiologic assessments of response to IP.
  16. Has undergone allogeneic stem cell transplantation or organ transplantation.
  17. Known history or positive test for human immunodeficiency virus, or positive test for hepatitis B (positive for hepatitis B surface antigen [HBsAg]) or hepatitis C virus ([HCV]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid [RNA]).

    • (NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody [HBcAb] positive, but HBsAg negative are eligible for enrollment. HCV: Subjects who are HCV Ab positive, but HCV RNA negative are eligible for enrollment).

Sites / Locations

  • The Sarah Cannon Research Institute
  • The University of Texas MD Anderson Cancer Center
  • Leuven Cancer Institute
  • Princess Margaret Cancer Center
  • Vall d'Hebron Institut D' Oncologia

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SL-279252

Arm Description

Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated

Outcomes

Primary Outcome Measures

Safety profile of SL-279252 - Incidence of all treatment emergent adverse events
Incidence of all treatment emergent adverse events
Maximum Tolerated Dose (MTD) of SL-279252
Defined based on the rate of dose limiting toxicities (DLTs)

Secondary Outcome Measures

Establish the recommended phase 2 dose of SL-279252
Establish the recommended phase 2 dose of SL-279252
Overall Response Rate of SL-279252
Response assessment according to immune response evaluation criteria in solid tumors (iRECIST) for solid tumors or response evaluation criteria in lymphoma (RECIL) 2017 for lymphomas Objective response rate (ORR; proportion of participants whose best overall response is a complete response [CR] or partial response [PR] evaluated via iRECIST. Clinical benefit rate (CBR; proportion of participants whose best overall response is an iCR, iPR or stable disease (iSD) of >12 weeks); minor response (MR) will be included for lymphomas
Immunogenicity to SL-279252
Number and proportion of participants with positive anti-drug antibody titer
Maximum serum concentration (Cmax) of SL-279252
The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
Minimum serum concentration (Cmin) of SL-279252
The Cmin is the minimum observed serum concentration of SL-279252 following single and multiple doses
Time at which maximum concentration of SL-279252 is observed (Tmax)
The Tmax is the time at which the maximum concentration of SL-279252 is observed following single and multiple doses
Area under the serum concentration-time curve (AUC)
The AUC is the area under the serum concentration time curve following single and multiple doses of SL-279252
Terminal half life (t1/2)
The t1/2 elimination half-life of SL-279252
Clearance
Clearance of SL-279252
Volume of distribution
Volume of distribution of SL-279252

Full Information

First Posted
January 10, 2019
Last Updated
February 24, 2023
Sponsor
Shattuck Labs, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03894618
Brief Title
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Official Title
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 26, 2019 (Actual)
Primary Completion Date
July 30, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shattuck Labs, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
Detailed Description
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas. The study design consists of Dose Escalation and Dose Expansion Cohorts. In the dose escalation phase of the study, subjects will be enrolled into sequential dose levels. During dose escalation, two possible schedules for administration of SL-279252 may be explored. The MTD or MAD may be determined for either schedule. Based on accumulating data from the dose escalation phase, including safety, PK, pharmacodynamic and anti-tumor activity, up to two dose expansion cohorts may be opened. The primary objective of the expansion phase is to further refine the safety and tolerability of SL-279252. The expansion cohorts will evaluate one or two doses of SL-279252 using one selected schedule. At the end of dose escalation and dose expansion, safety, PK, anti-tumor activity, and pharmacodynamic data will be reviewed to identify the RP2D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma of the Anus, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma of the Skin, Renal Cell Carcinoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mismatch Repair Deficient or MSI-High Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
87 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SL-279252
Arm Type
Experimental
Arm Description
Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
Intervention Type
Drug
Intervention Name(s)
SL-279252
Intervention Description
The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
Primary Outcome Measure Information:
Title
Safety profile of SL-279252 - Incidence of all treatment emergent adverse events
Description
Incidence of all treatment emergent adverse events
Time Frame
From Day 1 to 90 days after Last Dose of SL-279252 (approximately 1 year)
Title
Maximum Tolerated Dose (MTD) of SL-279252
Description
Defined based on the rate of dose limiting toxicities (DLTs)
Time Frame
From Day 1 to 90 days after Last Dose of SL-279252 (approximately 1 year)
Secondary Outcome Measure Information:
Title
Establish the recommended phase 2 dose of SL-279252
Description
Establish the recommended phase 2 dose of SL-279252
Time Frame
Approximately 32 months
Title
Overall Response Rate of SL-279252
Description
Response assessment according to immune response evaluation criteria in solid tumors (iRECIST) for solid tumors or response evaluation criteria in lymphoma (RECIL) 2017 for lymphomas Objective response rate (ORR; proportion of participants whose best overall response is a complete response [CR] or partial response [PR] evaluated via iRECIST. Clinical benefit rate (CBR; proportion of participants whose best overall response is an iCR, iPR or stable disease (iSD) of >12 weeks); minor response (MR) will be included for lymphomas
Time Frame
Approximately 32 months
Title
Immunogenicity to SL-279252
Description
Number and proportion of participants with positive anti-drug antibody titer
Time Frame
Approximately 32 months
Title
Maximum serum concentration (Cmax) of SL-279252
Description
The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
Time Frame
Approximately 32 months
Title
Minimum serum concentration (Cmin) of SL-279252
Description
The Cmin is the minimum observed serum concentration of SL-279252 following single and multiple doses
Time Frame
Approximately 32 months
Title
Time at which maximum concentration of SL-279252 is observed (Tmax)
Description
The Tmax is the time at which the maximum concentration of SL-279252 is observed following single and multiple doses
Time Frame
Approximately 32 months
Title
Area under the serum concentration-time curve (AUC)
Description
The AUC is the area under the serum concentration time curve following single and multiple doses of SL-279252
Time Frame
Approximately 32 months
Title
Terminal half life (t1/2)
Description
The t1/2 elimination half-life of SL-279252
Time Frame
Approximately 32 months
Title
Clearance
Description
Clearance of SL-279252
Time Frame
Approximately 32 months
Title
Volume of distribution
Description
Volume of distribution of SL-279252
Time Frame
Approximately 32 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. Subject has a histologically confirmed diagnosis of one of the following unresectable locally advanced or metastatic malignancies: melanoma, non-small cell lung cancer (squamous, adeno, or adeno-squamous), urothelial cancer, squamous cell carcinoma of the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of the anal canal, squamous cell carcinoma of the skin, renal cell cancer, Hodgkin's lymphoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (MMRD) solid tumors excluding CNS malignancies. MSI and MMRD testing results as per institution is acceptable. Head and neck cancers: Subjects must have primary tumor locations in the oropharynx, oral cavity, hypopharynx, or larynx. Primary tumor sites of nasopharynx, maxillary sinus, paranasal, and unknown primary are excluded. Non-small cell lung cancers: Subjects with a known EGFR sensitizing (activating) mutation or an ALK fusion are excluded. Subject must have received, been intolerant to, or is ineligible for standard therapy (per local guidelines and approvals) or have a malignancy for which there is no approved therapy considered standard of care. Age 18 years and older. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. Has measurable disease by iRECIST (solid tumors) or RECIL 2017 (lymphoma). Refer to Appendix Sections 16.6 and 16.7 for details on criteria of measurable disease. Has life expectancy of greater than 12 weeks. Laboratory values must meet the following criteria. Laboratory parameter Threshold value Absolute lymphocyte count (ALC) ≥ 0.8 x 109/liter (L) Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support Platelet count ≥ 50 x 109/L Laboratory parameter Threshold value Hemoglobin (Hgb) > 9.0 g/dL with no blood transfusions for at least 5 days prior to D1 of investigational product (IP; SL-279252) Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/min (modified Cockcroft-Gault) ALT/AST ≤ 3 x ULN Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is <35% and total bilirubin is ≤ 3.0 x ULN Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) ≥ lower limit of normal (LLN) per institutional threshold. If LLN is not defined for a given institution, then ejection fraction must be ≥50 %. Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP. NOTE: FCBP unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally postmenopausal for at least 12 consecutive months (see Appendix Section 16.2 for additional details). Documentation of postmenopausal status must be provided. FCBP should use an acceptable method of contraception (see Appendix Section 16.2) to avoid pregnancy during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of IP. FCBP must start using acceptable contraception at least 14 days prior to D1 of IP. Male subjects with female partners must have azoospermia from a prior vasectomy or underlying medical condition or agree to use an acceptable method of contraception during treatment and for 30 days (which exceeds 5 half-lives) after last dose of SL-279252 (see Appendix Section 16.2). Male subjects of reproductive potential must start using acceptable contraception at least 14 days prior to D1 of treatment with SL-279252 as per Appendix Section 16.2. All AEs resulting from prior anti-cancer immunotherapy have resolved (NOTE: exceptions include alopecia, vitiligo, and endocrinopathies adequately treated with hormone replacement). • Subjects that were discontinued from prior PD-1/L1 therapy due to immune-related adverse events are not eligible Recovery from toxicities from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade toxicities (e.g., alopecia, ≤ Grade 2 lymphopenia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy) may be allowed at the discretion of the investigator if considered clinically insignificant. Please consult the Sponsor Medical Monitor to discuss these cases). Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: Has received more than two prior checkpoint inhibitor containing treatment regimens (regimen refers to either monotherapy or combination immunotherapies) or has had prior treatment with an OX40 agonist. • Prior PD-1/L1 therapy is not required. Refractory to last PD-1/L1 inhibitor-based therapy which is defined as disease progression within 3 months of treatment initiation. • Subjects must have had clinical benefit (stable disease or response) to last PD-1/L1 inhibitor-based therapy for at least three months to be eligible. Any anti-cancer therapy within the time intervals noted below prior to first dose (D1) of SL-279252. Therapy Washout period Chemotherapy 3 weeks Hormonal therapy 3 weeks PD-1/L1 inhibitor and other immunotherapies not otherwise specified 3 weeks Tumor vaccine 4 weeks Cell-based therapy 8 weeks Other mAbs or biologic therapies 3 weeks Major surgery 2 weeks Radiation (except palliative intent which does not require washout) 2 weeks Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy is prohibited. Concurrent use of hormones for non-cancer related conditions is acceptable. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of D1 of IP with the following exceptions (i.e., the following are allowed during treatment with or within14 days of D1 of IP): Topical, intranasal, inhaled, ocular, intraarticular corticosteroids Physiological doses of replacement steroid (e.g., for adrenal insufficiency) provided ≤ 10 mg/day of prednisone or equivalent Steroid premedication for hypersensitivity reactions (HSRs; e.g., reaction to IV contrast) Receipt of live attenuated vaccine within 28 days of D1 of IP. Active or documented history of autoimmune disease (autoimmune disease does not refer to irAEs; for irAEs see inclusion criteria #11). Exceptions include Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism. Active pneumonitis (i.e. drug-induced, idiopathic pulmonary fibrosis, radiation-induced, etc.). Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of IP). Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal (GI) disease associated with diarrhea within 6 months of D1 of IP. Clinically significant or uncontrolled cardiac disease including any of the following: Myocarditis Unstable angina within 6 months from D1 of IP Acute myocardial infarction within 6 months from D1 of IP Uncontrolled hypertension New York Heart Association (NYHA) Class II, III or IV congestive heart failure Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia requiring therapy) Untreated central nervous system (CNS) or leptomeningeal metastases. Subjects with treated CNS metastases must have completed definitive treatment (radiotherapy and/or surgery) > 2 weeks prior to D1 of IP and no longer require steroids. Women who are breast feeding. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent. Another malignancy that requires active therapy and that in the opinion of the investigator and Sponsor would interfere with monitoring of radiologic assessments of response to IP. Has undergone allogeneic stem cell transplantation or organ transplantation. Known history or positive test for human immunodeficiency virus, or positive test for hepatitis B (positive for hepatitis B surface antigen [HBsAg]) or hepatitis C virus ([HCV]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid [RNA]). (NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody [HBcAb] positive, but HBsAg negative are eligible for enrollment. HCV: Subjects who are HCV Ab positive, but HCV RNA negative are eligible for enrollment).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shattuck Labs
Organizational Affiliation
Shattuck Labs
Official's Role
Study Director
Facility Information:
Facility Name
The Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Leuven Cancer Institute
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Princess Margaret Cancer Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1Z5
Country
Canada
Facility Name
Vall d'Hebron Institut D' Oncologia
City
Barcelona
ZIP/Postal Code
08035
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

We'll reach out to this number within 24 hrs